Your search returned 3 results.

Results
	1.	Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. [electronic resource] by Herting, Frank Friess, Thomas Bader, Sabine Muth, Gunter Hölzlwimmer, Gabriele Rieder, Natascha Umana, Pablo Klein, Christian Producer: 20150423 In: Leukemia & lymphoma vol. 55 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. [electronic resource] by Herter, Sylvia Herting, Frank Muth, Gunter van Puijenbroek, Erwin Schlothauer, Tilman Ferrara, Claudia Brady, Kevin Lang, Sabine Bacac, Marina Mössner, Ekkehard Umana, Pablo Klein, Christian Producer: 20190219 In: Haematologica vol. 103 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. [electronic resource] by Herter, Sylvia Herting, Frank Mundigl, Olaf Waldhauer, Inja Weinzierl, Tina Fauti, Tanja Muth, Gunter Ziegler-Landesberger, Doris Van Puijenbroek, Erwin Lang, Sabine Duong, Minh Ngoc Reslan, Lina Gerdes, Christian A Friess, Thomas Baer, Ute Burtscher, Helmut Weidner, Michael Dumontet, Charles Umana, Pablo Niederfellner, Gerhard Bacac, Marina Klein, Christian Producer: 20140519 In: Molecular cancer therapeutics vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)